Read more

August 05, 2021
1 min read
Save

Top in hem/onc: Smartphone algorithm for anemia, rising costs of metastatic breast cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

New research revealed that an algorithm for anemia detection using smartphone photos performed with 72.6% accuracy. It was the top story in hematology/oncology last week.

Another top story included results from a study about metastatic breast cancer. Researchers hypothesized that total annual costs of metastatic breast cancer could spike due to the estimated rise in cases among younger women.

Money and Stethoscope
Source: Adobe Stock

Read these and more top stories in hematology/oncology below:

Algorithm enables detection of anemia from smartphone photos of the inner eyelid

Anemia is a global public health problem that carries significant risk for mortality and morbidity, particularly among older adults, children and individuals with chronic conditions. Read more.

Costs of metastatic breast cancer could jump 140% by 2030

Total annual costs associated with metastatic breast cancer in the U.S. could exceed $152 billion in 2030, according to a study published in JNCI Cancer Spectrum. Read more.

Screening method frequently misses endometrial cancer in Black women

Transvaginal ultrasound used to determine appropriateness of endometrial cancer biopsy missed nearly five times more cases of the disease among Black women vs. white women, according to a simulated cohort study published in JAMA Oncology. Read more.

The University of Texas MD Anderson Cancer Center again ranked best cancer hospital in US

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country. Read more.

Bristol Myers Squibb withdraws liver cancer indication for nivolumab

Bristol Myers Squibb in consultation with the FDA voluntarily withdrew the indication for nivolumab (Opdivo) as monotherapy for patients with hepatocellular carcinoma previously treated with sorafenib (Nexavar, Bayer). Read more.